29 terminated. 29 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 29 | Terminated 29 |
| Phase 2 | 8 | Terminated 8 |
Follow Hepatitis, Chronic: new trials by email Literature Review of Hepatitis, Chronic trials Research Report on Hepatitis, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 YS-HBV-002 - Chronic Hepatitis B | Phase 1 | Terminated | Yisheng Biopharma (Singapore) Pte. Ltd. | 16 | 2024-07-01 | 2025-02-24 |
| A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection 162, Placebo - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Yangshengtang Co., Ltd | 1 | 2024-06-03 | 2024-07-16 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment - Chronic Hepatitis B | Phase 1 | Terminated | Hoffmann-La Roche | 60 | 2023-04-28 | 2026-01-22 |
| A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects ALG-125755, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 57 | 2022-10-07 | 2024-03-15 |
| A Single and Multiple Ascending Dose Study of JNJ-64457744 JNJ-64457744, Placebo, Tenofovir Disoproxil Fumarate (TDF) - Healthy, Hepatitis B, Chronic | Phase 1 | Terminated | Janssen Research & Development, LLC | 60 | 2022-07-04 | 2025-02-03 |
| Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection GSK3965193, Placebo to match GSK3965193, Bepirovirsen - Hepatitis B | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 74 | 2022-04-14 | 2026-10-14 |
| Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects ATI-2173 50 mg - Chronic Hepatitis b | Phase 1 | Terminated | Antios Therapeutics, Inc | 37 | 2022-03-29 | 2022-11-18 |
| A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects ALG-020572, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 40 | 2021-09-25 | 2023-04-25 |
| A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. EDP-721, Placebo (Part 1), EDP-721 (Part 2) - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Enanta Pharmaceuticals, Inc | 26 | 2021-08-02 | 2022-02-14 |
| Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection AB-836, Placebo, Nucleos(t)ide Analogue - Chronic Hepatitis | Phase 1 | Terminated | Arbutus Biopharma Corporation | 110 | 2021-06-25 | 2022-11-21 |
| Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study HEC121120 tablets, HEC121120 placebo tablets, entecavir tablets - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | Sunshine Lake Pharma Co., Ltd. | 52 | 2020-10-09 | 2024-06-24 |
| A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects ALG-010133, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 103 | 2020-08-17 | 2022-03-15 |
| Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis Orencia® (Abatacept) - Autoimmune Hepatitis | Phase 1 | Terminated | Stuart Knechtle, M.D. | 1 | 2020-03-09 | 2021-11-29 |
| Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 236 | 2019-03-28 | 2026-02-20 |
| Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers AL-3778, Entecavir, Tenofovir disoproxil fumarate - Hepatitis B, Chronic Hepatitis B | Phase 1 | Terminated | Alios Biopharma Inc. | 54 | 2017-01-31 | 2017-10-16 |
| A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection ALN-HBV, Sterile Normal Saline (0.9% NaCl) - Hepatitis B, Chronic Hepatitis B | Phase 1 | Terminated | Alnylam Pharmaceuticals | 24 | 2016-06-24 | 2018-09-24 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients Matching Placebo, RO7020322 - Hepatitis B, Chronic | Phase 1 | Terminated | Hoffmann-La Roche | 49 | 2015-11-28 | 2017-05-25 |
| Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects IDX21459, Matching Placebo - Chronic Hepatitis C | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 48 | 2014-03-01 | 2016-01-26 |
| A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients Sitagliptin - Hepatitis C | Phase 1 | Terminated | Institut National de la Santé Et de la Recherche Médicale, France | 3 | 2013-03-01 | 2026-10-07 |
| A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002) MK-8325, Placebo - Hepatitis C, Chronic | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 37 | 2012-04-01 | 2015-07-21 |
Showing 20 of 29. Sign in to see all of them.
Hepatitis B, Chronic (16) · Hepatitis C, Chronic (11) · Hepatitis B (5) · Hepatitis C (4) · Bronchiolitis Obliterans Syndrome (1) · Hepatitis, Autoimmune (1) · Liver Diseases (1)
Digestive System Diseases (29) · Hepatitis (29) · Chronic Disease (28) · Disease Attributes (28) · Liver Diseases (28) · Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Blood-Borne Infections (27) · Communicable Diseases (27) · Hepatitis, Viral, Human (27) · Infections (27) · Virus Diseases (27) · DNA Virus Infections (16) · Hepadnaviridae Infections (16)
entecavir (3) · Tenofovir (2) · Abatacept (1) · Dosage Forms (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · MK-8325 (1) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (1) · NVR 3-778 (1) · Nucleobindins (1) · Sitagliptin Phosphate (1) · Therapeutics (1) · albinterferon alfa-2b (1) · peginterferon alfa-2a (1) · pidilizumab (1) · tenofovir alafenamide (1)
Aligos Therapeutics (3) · GlaxoSmithKline (3) · Merck Sharp & Dohme LLC (3) · Alios Biopharma Inc. (2) · Hoffmann-La Roche (2) · Alnylam Pharmaceuticals (1) · Antios Therapeutics, Inc (1) · Anza Therapeutics, Inc. (1) · Arbutus Biopharma Corporation (1) · Arrow Therapeutics (1) · Bader, Ted, M.D. (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · CureTech Ltd (1) · Enanta Pharmaceuticals, Inc (1) · Institut National de la Santé Et de la Recherche Médicale, France (1)
New Zealand (12) · Hong Kong (7) · United Kingdom (6) · United States (6) · South Korea (5) · Thailand (5) · Australia (4) · Taiwan (4) · China (3) · France (3) · Moldova (3) · Canada (2) · Poland (2) · Spain (2) · Belgium (1)
Brian Sanderson (1) · David Mutimer (1) · Edward Gane (1) · Ike Minerva, MD (1) · Stephen Huang, MD (1) · Stuart Knechtle, MD (1) · Ted Bader, M.D. (1) · William D Kennedy, MD (1)
PMID 24995515, PMID 27137491, PMID 37290591, PMID 40118118
2017 (1), 2023 (1)